Sintesis Omeprazol untuk Penghambat Pompa Proton

Mengontrol asam lambung dengan kimia selektif kiral

Pharmaceutical & Drug Manufacturing Global Industrial Scale $3.5 billion

Ikhtisar

Omeprazole is the first proton pump inhibitor (PPI) to reach the market and remains one of the most prescribed medications globally for treating gastric acid disorders, peptic ulcers, and GERD. The synthesis involves a multi-step process building the benzimidazole-pyridine core structure. The chiral version, esomeprazole (the S-enantiomer), represents a significant pharmaceutical advancement, produced using an asymmetric oxidation that won AstraZeneca substantial patent protection.

Proses Kimia

2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.

Thioether intermediate + m-CPBA → Omeprazole (sulfoxide)
For esomeprazole: Ti(OiPr)₄/(R,R)-DET/cumene hydroperoxide → S-omeprazole (>99.5% ee)

Bahan Baku

  • 5-Methoxy-2-mercaptobenzimidazole — Multi-step synthesis from o-phenylenediamine (Core structure)
  • 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine — Pyridine chemistry (Pyridine moiety)
  • m-CPBA (meta-chloroperoxybenzoic acid) — Chemical synthesis (Oxidizing agent)

Produk Akhir

  • Omeprazole (C₁₇H₁₉N₃O₃S) — Proton pump inhibitor for GERD and ulcers (Racemic or enantiopure form)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.

Pertimbangan Keselamatan

Inovasi Terbaru

Biocatalytic oxidation using engineered cytochrome P450 enzymes and Baeyer-Villiger monooxygenases offers enantioselective sulfoxidation under mild conditions, potentially replacing chemical oxidants entirely.

Skala Produksi

800

ton/tahun

$3.5 billion

nilai pasar

Lebih banyak di %(name)s Pharmaceutical & Drug Manufacturing

Produksi Amoksisilin Semi-Sintetik

Global Industrial Scale

Produksi Insulin Manusia Rekombinan

Global Industrial Scale

Produksi Penisilin G dengan Fermentasi

Global Industrial Scale

Sintesis Aspirin melalui Asetilasi Asam Salisilat

Global Industrial Scale

Sintesis Ibuprofen — Proses Hijau BHC

Global Industrial Scale

Sintesis Metformin Hidroklorida

Global Industrial Scale

Sintesis Parasetamol (Asetaminofen)

Global Industrial Scale

Frequently Asked Questions

What industry uses Sintesis Omeprazol untuk Penghambat Pompa Proton?
Sintesis Omeprazol untuk Penghambat Pompa Proton is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in Sintesis Omeprazol untuk Penghambat Pompa Proton?
2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.
What is the economic significance of Sintesis Omeprazol untuk Penghambat Pompa Proton?
Sintesis Omeprazol untuk Penghambat Pompa Proton has a market value of $3.5 billion and annual production of 800 tons.
What is the environmental impact of Sintesis Omeprazol untuk Penghambat Pompa Proton?
Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.
What raw materials are used in Sintesis Omeprazol untuk Penghambat Pompa Proton?
The main raw materials include: 5-Methoxy-2-mercaptobenzimidazole, 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine, m-CPBA (meta-chloroperoxybenzoic acid).